DexCom (NASDAQ:DXCM) Price Target Raised to $160.00

DexCom (NASDAQ:DXCM - Free Report) had its price target lifted by Raymond James from $151.00 to $160.00 in a report issued on Friday, Benzinga reports. They currently have a strong-buy rating on the medical device company's stock.

Several other analysts have also weighed in on DXCM. Royal Bank of Canada began coverage on DexCom in a report on Tuesday, March 12th. They issued an outperform rating and a $165.00 price objective for the company. Canaccord Genuity Group upped their price objective on DexCom from $144.00 to $145.00 and gave the company a buy rating in a report on Friday. StockNews.com lowered DexCom from a buy rating to a hold rating in a report on Tuesday. UBS Group upped their price objective on DexCom from $153.00 to $163.00 and gave the company a buy rating in a report on Wednesday, April 10th. Finally, Citigroup upped their target price on DexCom from $148.00 to $161.00 and gave the company a buy rating in a report on Wednesday, April 3rd. Three equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of Moderate Buy and an average price target of $141.67.

DexCom Stock Performance

DXCM stock traded down $13.67 during trading on Friday, reaching $124.34. 8,576,828 shares of the company's stock were exchanged, compared to its average volume of 3,047,021. The company has a quick ratio of 2.48, a current ratio of 2.84 and a debt-to-equity ratio of 1.18. DexCom has a 1-year low of $74.75 and a 1-year high of $142.00. The company's fifty day moving average price is $130.98 and its 200-day moving average price is $118.02. The firm has a market cap of $49.24 billion, a PE ratio of 97.41, a P/E/G ratio of 2.37 and a beta of 1.20.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.05. The business had revenue of $921.00 million during the quarter, compared to analyst estimates of $911.20 million. DexCom had a return on equity of 28.31% and a net margin of 14.95%. On average, research analysts expect that DexCom will post 1.76 EPS for the current fiscal year.

Insider Activity at DexCom

In related news, EVP Matthew Vincent Dolan sold 1,990 shares of the company's stock in a transaction on Monday, April 15th. The stock was sold at an average price of $137.81, for a total transaction of $274,241.90. Following the transaction, the executive vice president now directly owns 42,377 shares of the company's stock, valued at $5,839,974.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other DexCom news, CEO Kevin R. Sayer sold 81,007 shares of the company's stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total value of $10,803,093.52. Following the transaction, the chief executive officer now directly owns 333,526 shares of the company's stock, valued at approximately $44,479,027.36. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Matthew Vincent Dolan sold 1,990 shares of the company's stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $137.81, for a total value of $274,241.90. Following the completion of the transaction, the executive vice president now directly owns 42,377 shares in the company, valued at $5,839,974.37. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 189,375 shares of company stock valued at $25,530,859. Company insiders own 0.41% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Stableford Capital II LLC increased its holdings in shares of DexCom by 2.1% during the 4th quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company's stock valued at $563,000 after acquiring an additional 88 shares during the last quarter. D Orazio & Associates Inc. increased its holdings in shares of DexCom by 0.8% during the 4th quarter. D Orazio & Associates Inc. now owns 12,366 shares of the medical device company's stock valued at $1,534,000 after acquiring an additional 93 shares during the last quarter. Gulf International Bank UK Ltd increased its holdings in shares of DexCom by 0.3% during the 1st quarter. Gulf International Bank UK Ltd now owns 32,075 shares of the medical device company's stock valued at $4,448,000 after acquiring an additional 93 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of DexCom by 10.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the medical device company's stock valued at $133,000 after acquiring an additional 98 shares during the last quarter. Finally, Harbor Investment Advisory LLC increased its holdings in shares of DexCom by 13.1% during the 1st quarter. Harbor Investment Advisory LLC now owns 864 shares of the medical device company's stock valued at $120,000 after acquiring an additional 100 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.